Oxervate

Chemical Namecenegermin-bkbj
Dosage FormDrops (eye; 0.002% (20 mcg/mL)
Drug ClassOphthalmic agents
SystemOcular
CompanyDompé U.S. Inc.
Approval Year2018

Indication

  • To treat neurotrophic keratitis.
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Oxervate (Cenegermin-bkbj) Prescribing Information 2019Dompé U.S. Inc., Boston, M